Shanghai OPM Biosciences Co., Ltd.

688293

CNE100005PF1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-05-08			5-day change	1st Jan Change
51.88 ^CNY	-1.33%		+3.26%	+5.88%

Apr. 29	Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 01	Shanghai OPM Biosciences Co., Ltd. announced that it has received CNY 362.049828 million in funding from a group of investors	CI

Shanghai OPM Biosciences Co., Ltd. signed a letter of intent to acquire an unknown minority stake in PharmaLegacy Laboratories Co., Ltd. from PharmaLegacy Hong Kong Limited, Jiaxing Hetuo Enterprise Management Partnership (Limited Partnership) and Jiaxing Huituo Enterprise Management Partnership (Limited Partnership).

Published on 01/16/2025

S&P Capital IQ

SHANGHAI OPM BIOSCIENCES CO., LTD.

-1.33%

Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) signed a letter of intent to acquire an unknown minority stake in PharmaLegacy Laboratories (Shanghai) Co., Ltd. from PharmaLegacy Hong Kong Limited, Jiaxing Hetuo Enterprise Management Partnership (Limited Partnership) and Jiaxing Huituo Enterprise Management Partnership (Limited Partnership) on January 16, 2025.

Latest news about Shanghai OPM Biosciences Co., Ltd.

Apr. 29	Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 01	Shanghai OPM Biosciences Co., Ltd. announced that it has received CNY 362.049828 million in funding from a group of investors	CI
Feb. 27	Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 13	Shanghai OPM Biosciences Co., Ltd. completed the acquisition of PharmaLegacy Laboratories Co., Ltd. from a group of shareholders.	CI
Dec. 31	Shanghai OPM Biosciences plans to buy Pharmalegacy Laboratories	RE
25-10-29	Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-09-29	Shanghai OPM Biosciences Unit Passes EU Audit	MT
25-08-24	Certain A Shares of Shanghai OPM Biosciences Co., Ltd. are subject to a Lock-Up Agreement Ending on 25-AUG-2025.	CI
25-08-22	Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-14	OPM Biosciences' H1 Profit to Jump 53%	MT
25-04-28	Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-11	Shanghai Sureness Biotechnology Co., Ltd. announced that it has received CNY 199.9 million in funding from Shanghai OPM Biosciences Co., Ltd.	CI
25-02-27	Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-16	Shanghai OPM Biosciences Co., Ltd. announced that it expects to receive CNY 730 million in funding	CI
25-01-16	Shanghai OPM Biosciences Co., Ltd. signed a letter of intent to acquire an unknown minority stake in PharmaLegacy Laboratories Co., Ltd. from PharmaLegacy Hong Kong Limited, Jiaxing Hetuo Enterprise Management Partnership (Limited Partnership) and Jiaxing Huituo Enterprise Management Partnership (Limited Partnership).	CI

Chart Shanghai OPM Biosciences Co., Ltd.

Duration

Period

Chart Shanghai OPM Biosciences Co., Ltd.

688293: Dynamic Chart

Company Profile

Shanghai OPM Biosciences Co Ltd is a China-based company mainly engaged in cell culture products and services. The Company's main business involves two application areas: cell culture medium series products and biopharmaceutical contract development and production services. The Company's cell culture medium series products are widely used in the production of biological products such as protein/antibody production, vaccine production, cell therapy/gene therapy, and others. The Company's antibody drug development contract development and manufacturing organization (CDMO) service platform is committed to providing domestic and foreign customers with full-process services from antibody engineering humanization screening, cell line construction, process development to pilot production and clinical I&II phase sample production.

Employees

328

Sector

Pharmaceuticals

More about the company